Altamira Therapeutics Reaches Midpoint for Enrollment in Clinical Trial with Bentrio in Seasonal Allergic Rhinitis in Australia

Stock Information for Altamira Therapeutics Ltd.

Loading

Please wait while we load your information from QuoteMedia.

More Recent News About Altamira Therapeutics Ltd.

Altamira Therapeutics Announces Publication of Positive Results from Bentrio Trial in Seasonal Allergic Rhinitis in Top Peer Reviewed Journal
Altamira Therapeutics Provides Business Update, Reports Full Year 2023 Financial Results
Altamira Therapeutics to Host Full Year 2023 Financial Results and Business Update Call on April 10, 2024
Altamira Therapeutics Announces Collaboration with Univercells Group on Nanoparticle-Delivered mRNA Vaccines
Altamira Therapeutics' Peptide-Based Delivery Platform Shown to Enhance Potency of Commonly Used Gene Delivery Method as Published in Peer-Reviewed Journal
Altamira Therapeutics Files Second Provisional Patent Application for OligoPhore Nanoparticles Targeting Different KRAS Mutations in Cancer Treatment
Altamira Therapeutics to Present at 3rd Annual mRNA-Based Therapeutics Summit
Altamira Therapeutics Regains Compliance with Nasdaq Minimum Bid Price Requirement

Market data content copyright © QuoteMedia. Data delayed at least 15 minutes unless otherwise indicated (view Delay Times for all exchanges). Filings and Fundamentals by Morningstar. Insiders by Morningstar (USA) and SEDI (CDN). Analyst ratings by Zacks. Terms of Use.